Cytokinetics Valuation Multiples

Cytokinetics Overview

About Cytokinetics

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Founded

1997

HQ

Employees

498

Website

cytokinetics.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $89M

EBITDA: ($636M)

EV

$8B

Valuation Multiples

Multiples.vc

Start free trial

Cytokinetics Financials

Cytokinetics reported last 12-month revenue of $89M and negative EBITDA of ($636M).

In the same LTM period, Cytokinetics generated $88M in gross profit, ($636M) in EBITDA losses, and had net loss of ($788M).

Cytokinetics P&L

In the most recent fiscal year, Cytokinetics reported revenue of $88M and EBITDA of ($606M).

Cytokinetics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Cytokinetics Stock Performance

Cytokinetics has current market cap of $8B, and enterprise value of $8B.

Cytokinetics' stock price is $61.46.

Cytokinetics Valuation Multiples

Cytokinetics trades at 87.0x EV/Revenue multiple, and (12.2x) EV/EBITDA.

Cytokinetics Financial Valuation Multiples

As of March 24, 2026, Cytokinetics has market cap of $8B and EV of $8B.

Equity research analysts estimate Cytokinetics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Cytokinetics has a P/E ratio of (9.5x).

Cytokinetics Margins & Growth Rates

Cytokinetics' revenue in the last 12 month grew by 78%.

Cytokinetics' revenue per employee in the last FY averaged $0.2M.

Cytokinetics' rule of 40 is (636%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cytokinetics' rule of X is (518%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Cytokinetics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Cytokinetics M&A Activity

Cytokinetics acquired XXX companies to date.

Last acquisition by Cytokinetics was on XXXXXXXX, XXXXX. Cytokinetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Cytokinetics Investment Activity

Cytokinetics invested in XXX companies to date.

Cytokinetics made its latest investment on XXXXXXXX, XXXXX. Cytokinetics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).